Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Dayton
mi
from
Dayton, OH
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Lewistown Hospital
mi
from
Lewistown, PA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Lewistown Hospital
mi
from
Lewistown, PA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Mount Nittany Medical Center
mi
from
State College, PA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Chester County Hospital
mi
from
West Chester, PA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Chester County Hospital
mi
from
West Chester, PA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Greenville
mi
from
Greenville, SC
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Northwest
mi
from
Tacoma, WA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Instituto Nacional de Enfermedades Neoplasicas
mi
from
Lima,
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Instituto Nacional de Enfermedades Neoplasicas
mi
from
Lima,
Click here to add this to my saved trials
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
Status: Enrolling
Updated:  10/14/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
Status: Enrolling
Updated: 10/14/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors
Status: Enrolling
Updated:  10/14/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors
Status: Enrolling
Updated: 10/14/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Decatur, GA
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated:  10/16/2015
mi
from
Buenos Aires,
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Status: Enrolling
Updated: 10/16/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.
Status: Enrolling
Updated:  10/19/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.
Status: Enrolling
Updated: 10/19/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated:  10/20/2015
Indiana BMT
mi
from
Beech Grove, IN
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated: 10/20/2015
Indiana BMT
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated:  10/20/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated: 10/20/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever
Status: Enrolling
Updated:  10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever
Status: Enrolling
Updated: 10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
Assessment of Femarelle (DT56a), a Novel SERM, Effect on the Clotting Time in Normal and Thrombophililic Postmenopausal Women
Status: Enrolling
Updated:  10/20/2015
251 East 33rd Street
mi
from
New York, NY
Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
Assessment of Femarelle (DT56a), a Novel SERM, Effect on the Clotting Time in Normal and Thrombophililic Postmenopausal Women
Status: Enrolling
Updated: 10/20/2015
251 East 33rd Street
mi
from
New York, NY
Click here to add this to my saved trials
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
Status: Enrolling
Updated:  10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
Status: Enrolling
Updated: 10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital
mi
from
Lake Success, NY
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
Gabrail Cancer Center
mi
from
Canton, OH
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic
mi
from
Nashville, TN
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
Baylor Charles A Sammons Cancer Center
mi
from
Dallas, TX
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
Baylor Charles A Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated:  10/21/2015
Royal Prince Alfred Hospital
mi
from
Camperdown,
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Status: Enrolling
Updated: 10/21/2015
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
The Oncology Institute of Hope and Innovation
mi
from
Whittier, CA
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
The Oncology Institute of Hope and Innovation
mi
from
Whittier, CA
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Clinical Research Alliance
mi
from
New York, NY
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Clinical Research Alliance
mi
from
New York, NY
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Texas Oncology
mi
from
Austin, TX
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Texas Oncology
mi
from
Austin, TX
Click here to add this to my saved trials
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated:  10/21/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Status: Enrolling
Updated: 10/21/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials